SCHEMBL3569794

SCHEMBL3569794

CCOC(=O)c1cc2c(NC(C)=O)c(-c3ccc(OC(C)C)cc3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
ACACB O00763 2/20 0.39
ACACA Q13085 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 4/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574863 0.88 PTGES (0.52) PTGESSMN1; SMN2ACACBACACAKDM4E
SCHEMBL3571774 0.85 PTGES (0.43) PTGESSMN1; SMN2POLBKDM4EMAPT
SCHEMBL4698539 0.83 PTGES (0.41) PTGESSMN1; SMN2POLBKDM4EMAPT
SCHEMBL3581420 0.81 ALDH1A1 (0.41) PTGESSMN1; SMN2POLBMAPTMAPK1
SCHEMBL3575712 0.77 PTGES (0.64) PTGESSMN1; SMN2POLBKDM4EMAPT
SCHEMBL4086547 0.75 MAPT (0.46) PTGESSMN1; SMN2POLBKDM4EMAPT
SCHEMBL3001458 0.75 PTGES (0.51) PTGESSMN1; SMN2POLBKDM4EMAPT
SCHEMBL4923150 0.74 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EMAPTHTTMAPK1
SCHEMBL4916920 0.74 ELANE (0.41) SMN1; SMN2POLBKDM4EMAPTALDH1A1
SCHEMBL2997482 0.74 PTGES (0.50) PTGESSMN1; SMN2POLBKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705023-B2 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2010-04-27 US disclosed
EP-1778632-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-08-20 EP disclosed
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2007-12-13 US disclosed
EP-1778632-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-05-02 EP disclosed
WO-2005123673-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287715-A1 Indoles Useful in the Treatment of Inflammation PTGS1, IDO1, PTGES PTGES 3/4885SMN1; SMN2 4318/4885ACACB 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.